Association between genetic variants on chromosome 15q25 locus and objective measures of Tobacco exposure

Journal of the National Cancer Institute

Volumn 104, Issue 10, 2012, Pages 740-748

  Munafò, Marcus R ^a   Timofeeva, Maria N ^b   Morris, Richard W ^c   Prieto Merino, David ^d   Sattar, Naveed ^e   Brennan, Paul ^b   Johnstone, Elaine C ^f   Relton, Caroline ^g   Johnson, Paul C D ^h   Walther, Donna ⁱ   Whincup, Peter H ^j   Casas, Juan P ^c,d   Uhl, George R ⁱ   Vineis, Paolo ^k,l   Padmanabhan, Sandosh ^e   Jefferis, Barbara J ^c   Amuzu, Antoinette ^d   Riboli, Elio ^k   Upton, Mark N ^m   Aveyard, Paul ⁿ   Ebrahim, Shah ^c   Hingorani, Aroon D ^c   Watt, Graham ^o   Palmer, Tom M ^a   Timpson, Nicholas J ^a   Bierut, L J ^a   Davey Smith, George ^a   more..

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^e UNIVERSITY OF GLASGOW   (United Kingdom)

^f UNIVERSITY OF OXFORD   (United Kingdom)

^g NEWCASTLE UNIVERSITY   (United Kingdom)

^h UNIVERSITY OF GLASGOW   (United Kingdom)

ⁱ NATIONAL INSTITUTES OF HEALTH   (United States)

^j ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^k IMPERIAL COLLEGE LONDON   (United Kingdom)

^l School of Public Health and HuGeF Foundation   (Italy)

^m Woodlands Family Medical Centre   (United Kingdom)

ⁿ UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^o UNIVERSITY OF GLASGOW   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

COTININE;

ADULT; AGED; ALLELE; CANCER RISK; CHROMOSOME 15Q; CIGARETTE SMOKING; FEMALE; GENE LOCUS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; LUNG CANCER; MALE; PRIORITY JOURNAL; REVIEW; SELF REPORT; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84861325364     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djs191     Document Type: Review

References (56)

1. Amos CI, Wu XF, Broderick P, et al. Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat Genet. 2008;40(5):616-622.
2. Hung RJ, Mckay JD, Gaborieau V, et al. A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature. 2008;452(7187):633-637.
3. Thorgeirsson TE, Geller F, Sulem P, et al. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature. 2008;452(7187):638-639.
4. Pillai SG, Ge DL, Zhu GH, et al. A genome-wide association study in chronic obstructive pulmonary disease (COPD): identification of two major susceptibility loci. PloS Genet. 2009;5(3):e1000421.
5. Young RP, Hophins RJ, Hay BA, Epton MJ, Black PN, Gamble GD. Lung cancer gene associated with COPD: triple whammy or possible confounding effect? Eur Resp J. 2008;32(5):1158-1164.
6. Zintzaras E, Zdoukopoulos N. A field synopsis and meta-analysis of genetic association studies in peripheral arterial disease: the CUMAGAS-PAD database. Am J Epidemiol. 2009;170(1):1-11.
7. Freathy RM, Ring SM, Shields B, et al. A common genetic variant in the 15q24 nicotinic acetylcholine receptor gene cluster (CHRNA5-CHRNA3-CHRNB4) is associated with a reduced ability of women to quit smoking in pregnancy. Hum Mol Genet. 2009;18(15):2922-2927.
8. Freathy RM, Kazeem GR, Morris RW, et al. Genetic variation at CHRNA5-CHRNA3-CHRNB4 interacts with smoking status to influence body mass index. Int J Epidemiol. 2011;40(6):1617-1628.
9. Liu JZ, Tozzi F, Waterworth DM, et al. Meta-analysis and imputation refines the association of 15q25 with smoking quantity. Nat Genet. 2010;42(5):436-440.
10. Shiraishi K, Kohno T, Kunitoh H, et al. Contribution of nicotine acetylcholine receptor polymorphisms to lung cancer risk in a smoking-independent manner in the Japanese. Carcinogenesis. 2009;30(1):65-70.
11. Baker TB, Weiss RB, Bolt D, et al. Human neuronal acetylcholine receptor A5-A3-B4 haplotypes are associated with multiple nicotine dependence phenotypes. Nicotine Tob Res. 2009;11(7):785-796.
12. Breitling LP, Dahmen N, Mittelstrass K, et al. Association of nicotinic acetylcholine receptor subunit alpha 4 polymorphisms with nicotine dependence in 5500 Germans. Pharmacogenomics J. 2009;9(4):219-224.
13. Broderick P, Wang YF, Vijayakrishnan J, et al. Deciphering the impact of common genetic variation on lung cancer risk: a genome-wide association study. Cancer Res. 2009;69(16):6633-6641.
14. Chen XN, Chen JC, Williamson VS, et al. Variants in nicotinic acetylcholine receptors alpha 5 and alpha 3 increase risks to nicotine dependence. Am J Med Genet B Neuropsychiatr Genet. 2009;150B(7):926-933.
15. Lips EH, Gaborieau V, McKay JD, et al. Association between a 15q25 gene variant, smoking quantity and tobacco-related cancers among 17 000 individuals. Int J Epidemiol. 2010;39(2):563-577.
16. Saccone NL, Wang JC, Breslau N, et al. The CHRNA5-CHRNA3-CHRNB4 nicotinic receptor subunit gene cluster affects risk for nicotine dependence in African-Americans and in European-Americans. Cancer Res. 2009;69(17):6848-6856.
17. Schlaelpfer IR, Hoft NR, Collins AC, et al. The CHRNA5/A3/B4 gene cluster variability as an important determinant of early alcohol and tobacco initiation in young adults. Biol Psychiatry. 2008;63(11):1039-1046.
18. Sherva R, Wilhelmsen K, Pomerleau CS, et al. Association of a single nucleotide polymorphism in neuronal acetylcholine receptor subunit alpha 5 (CHRNA5) with smoking status and with 'pleasurable buzz' during early experimentation with smoking. Addiction. 2008;103(9):1544-1552.
19. Stevens VL, Bierut LJ, Talbot JT, et al. Nicotinic receptor gene variants influence susceptibility to heavy smoking. Cancer Epidemiol Biomarkers Prev. 2008;17(12):3517-3525.
20. Tobacco-and-Genetics-Consortium. Genome-wide meta-analyses identify multiple loci associated with smoking behavior. Nat Genet. 2010;42(5):441-447.
21. Ware JJ, van den Bree MB, Munafo MR. Association of the CHRNA5-A3-B4 gene cluster with heaviness of smoking: a meta-analysis. Nicotine Tob Res. 2011;13(12):1167-1175.
22. Thorgeirsson TE, Gudbjartsson DF, Surakka I, et al. Sequence variants at CHRNB3-CHRNA6 and CYP2A6 affect smoking behavior. Nat Genet. 2010;42(5):448-453.
23. Saccone SF, Hinrichs AL, Saccone NL, et al. Cholinergic nicotinic receptor genes implicated in a nicotine dependence association study targeting 348 candidate genes with 3713 SNPs. Hum Mol Genet. 2007;16(1):36-49.
24. Berrettini W, Yuan X, Tozzi F, et al. Alpha-5/alpha-3 nicotinic receptor subunit alleles increase risk for heavy smoking. Mol Psychiatry. 2008;13(4):368-373.
25. Bierut LJ, Stitzel JA, Wang JC, et al. Variants in nicotinic receptors and risk for nicotine dependence. Am J Psychiatry. 2008;165(9):1163-1171.
26. Shipton D, Tappin DM, Vadiveloo T, Crossley JA, Aitken DA, Chalmers J. Reliability of self reported smoking status by pregnant women for estimating smoking prevalence: a retrospective, cross sectional study. BMJ. 2009;339:b4347.
27. Keskitalo K, Broms U, Heliovaara M, et al. Association of serum cotinine level with a cluster of three nicotinic acetylcholine receptor genes (CHRNA3/CHRNA5/CHRNB4) on chromosome 15. Hum Mol Genet. 2009;18(20):4007-4012.
28. Le Marchand L, Derby KS, Murphy SE, et al. Smokers with the CHRNA lung cancer-associated variants are exposed to higher levels of nicotine equivalents and a carcinogenic tobacco-specific nitrosamine. Cancer Res. 2008;68(22):9137-9140.
29. Aveyard P, Brown K, Saunders C, et al. Weekly versus basic smoking cessation support in primary care: a randomised controlled trial. Thorax. 2007;62(10):898-903.
30. Baltar VT, Xun WW, Chuang SC, et al. Smoking, second-hand smoke and cotinine levels in a subset of EPIC cohort. Cancer Epidemiol Biomarkers Prev. 2011;20(5):869-875.
31. Hart CL, MacKinnon PL, Watt GC, et al. The Midspan studies. Int J Epidemiol. 2005;34(1):28-34.
32. Imperial-Cancer-Research-Fund. Effectiveness of a nicotine patch in helping people stop smoking: results of a randomised trial in general practice. BMJ. 1993;306(6888):1304-1308.
33. Johansson M, Relton C, Ueland PM, et al. Serum B vitamin levels and risk of lung cancer. JAMA. 2010;303(23):2377-2385.
34. Johnstone E, Benowitz N, Cargill A, et al. Determinants of the rate of nicotine metabolism and effects on smoking behavior. Clin Pharmacol Ther. 2006;80(4):319-330.
35. Lawlor DA, Bedford C, Taylor M, Ebrahim S. Geographical variation in cardiovascular disease, risk factors, and their control in older women: British Women's Heart and Health Study. J Epidemiol Community Health. 2003;57(2):134-140.
36. Middtun O, Hustad S, Ueland PM. Quantitative profiling of biomarkers related to B-vitamin status, tryptophan metabolism and inflammation in human plasma by liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom. 2009;23(9):1371-1379.
37. Munafo MR, Johnstone E, Walther D, Uhl GR, Murphy M, Aveyard P. CHRNA3 rs1051730 genotype and short-term smoking cessation. Nicotine Tob Res. 2011;13(10):982-988.
38. Riboli E, Hunt KJ, Slimani N, et al. European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. Public Health Nutr. 2002;5(6B):1113-1124.
39. Walker M, Whincup PH, Shaper AG. The British Regional Heart Study 1975-2004. Int J Epidemiol. 2004;33(6):1185-1192.
40. Yudkin P, Hey K, Roberts S, Welch S, Murphy M, Walton R. Abstinence from smoking eight years after participation in randomised controlled trial of nicotine patch. BMJ. 2003;327(7405):28-29.
41. Timofeeva MN, McKay JD, Smith GD, et al. Genetic polymorphisms in 15q25 and 19q13 loci, cotinine levels, and risk of lung cancer in EPIC. Cancer Epidemiol Biomarkers Prev. 2011;20(10):2250-2261.
42. Pinheiro JC, Bates DM. Mixed-Effects Models in S and S-PLUS. New York, NY: Springer; 2000.
43. Etter JF, Vu Duc T, Perneger TV. Saliva cotinine levels in smokers and nonsmokers. Am J Epidemiol. 2000;151(3):251-258.
44. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177-188.
45. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557-560.
46. Boffetta P, Clark S, Shen M, Gislefoss R, Peto R, Andersen A. Serum cotinine level as predictor of lung cancer risk. Cancer Epidemiol Biomarkers Prev. 2006;15(6):1184-1188.
47. Society-for-Research-on-Nicotine-and-Tobacco. Biochemical verification of tobacco use and cessation. Nicotine Tob Res. 2002;4(2):149-159.
48. Davey-Smith G, Ebrahim S. 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol. 2003;32(1):1-22.
49. Strasser AA, Lerman C, Sanborn PM, Pickworth WB, Feldman EA. New lower nicotine cigarettes can produce compensatory smoking and increased carbon monoxide exposure. Drug Alcohol Depend. 2007;86(2-3):294-300.
50. Parish S, Collins R, Peto R, et al. Cigarette smoking, tar yields, and non-fatal myocardial infarction: 14,000 cases and 32,000 controls in the United Kingdom. The International Studies of Infarct Survival (ISIS) Collaborators. BMJ. 1995;311(7003):471-477.
51. Hammond D, Fong GT, Cummings KM, O'Connor RJ, Giovino GA, McNeill A. Cigarette yields and human exposure: a comparison of alternative testing regimens. Cancer Epidemiol Biomarkers Prev. 2006;15(8):1495-1501.
52. Hart CL, Davey-Smith G, Hole DJ, Hawthorne VM. Carboxyhaemoglobin concentration, smoking habit, and mortality in 25 years in the Renfrew/Paisley prospective cohort study. Heart. 2006;92(3):321-324.
53. Phillips AN, Davey-Smith G. Bias in relative odds estimation owing to imprecise measurement of correlated exposures. Stat Med. 1992;11(7):953-961.
54. Tutka P, Mosiewicz J, Wielosz M. Pharmacokinetics and metabolism of nicotine. Pharmacol Rep. 2005;57(2):143-153.
55. Tyndale RF, Sellers EM. Variable CYP2A6-mediated nicotine metabolism alters smoking behavior and risk. Drug Metab Dispos. 2001;29(4, pt 2):548-552.
56. Mwenifumbo JC, Sellers EM, Tyndale RF. Nicotine metabolism and CYP2A6 activity in a population of black African descent: impact of gender and light smoking. Drug Alcohol Depend. 2007;89(1):24-33.